• Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer).
  • Approval addresses a significant unmet need, helping physicians to differentiate recurrent or progressive glioma from treatment-related change in adults and pediatric patients.
  • FET-PET imaging is recommended in international clinical practice guidelines, including NCCN Guidelines®.
  • Pixclara expands Telix’s industry-leading Precision Medicine business and reinforces the Company’s leadership in diagnostics and targeted radiopharmaceutical therapies (together, “theranostics”).

MELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Pixclara® (floretyrosine F 18 or 18F-FET), an amino acid positron emission tomography (PET) drug for imaging gliomas (brain cancer).

Pixclara is a radioactive diagnostic drug indicated for use with positron emission tomography (PET) to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients 1 month of age and older.

PET imaging with floretyrosine F 18 (FET-PET) is recommended in international clinical practice guidelines for the imaging of gliomas, including NCCN Guidelines®1, but until now there has not been an FDA-approved product available in the U.S.

Gliomas are the most common form of central nervous system (CNS) cancer, accounting for approximately 30% of all brain and CNS tumors and 80% of all malignant brain tumors2. In the U.S., approximately 24,000 new glioma cases are diagnosed each year3, representing a significant unmet addressable need.

Kevin Richardson, Chief Executive Officer, Telix Precision Medicine, said, “FDA approval of Pixclara will enable broad access in the U.S. to FET-PET imaging, which is already recognized in international clinical practice guidelines. As the first FDA-approved PET imaging drug for glioma, Pixclara will provide physicians in the U.S. with more certainty in their diagnoses and greater confidence in their treatment planning for patients.”

Kelly Sitkin, President and CEO, American Brain Tumor Association, said, “The approval of Pixclara will advance glioma care by enabling more precise monitoring, complementing the role of MRI. We welcome the FDA’s decision, which provides a pathway to access this technology in the U.S. and helps address a critical unmet need in brain cancer diagnostics.”

Patrick Wen, MD, E. Antonio Chiocca, MD, PhD, Family Endowed Chair in Neuro-Oncology at Mass General Brigham Cancer Institute, said, “Having an FDA-approved FET-PET product with high diagnostic accuracy will make a significant, positive difference to the management of patients with gliomas. This is a very positive step forward for brain cancer imaging and treatment planning.”

About Pixclara (floretyrosine F 18)

Pixclara® is an intravenous positron emission tomography (PET) imaging drug for the differentiation of recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients 1 month of age and older. It comprises a small molecule targeting compound labeled with a diagnostic radioisotope, fluorine-18. After administration into the bloodstream, Pixclara targets membrane transport proteins known as L-type amino acid transporters 1 and 2 (LAT1 and LAT2). Once bound, energy emissions from the radioisotope can be detected by a PET scanner. Pixclara (TLX101-Px) is also the subject of a Phase 3 registrational study for potential indication expansion for the diagnosis of brain metastases4.

Pixclara is the only FDA-approved radiopharmaceutical imaging drug for glioma (brain cancer).

INDICATIONS AND USAGE 
PIXCLARA is indicated for use with positron emission tomography (PET) to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients 1 month of age and older.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS
Risk for Misinterpretation
Image misinterpretation may occur with PIXCLARA PET. A negative image does not rule out the presence of recurrent or progressive glioma and a positive image does not confirm the presence of recurrent or progressive glioma. Equivocal findings may occur with PIXCLARA PET, including low-level or atypical uptake patterns, which may result in false positive or false negative interpretations.

Interpret PIXCLARA PET findings with caution and correlate results with available clinical evaluations, such as histopathology, cross-sectional imaging, and/or clinical history to support appropriate clinical decision-making.

Radiation Risks
PIXCLARA contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Ensure safe drug handling to protect patients and health care providers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration.

ADVERSE REACTIONS
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of PIXCLARA was evaluated in 382 patients with gliomas. Among these 382 patients, 371 adult patients received at least one intravenous dose of PIXCLARA at a mean activity of 204 ± 18 MBq (5.5 ± 0.47 mCi). The remaining 11 pediatric patients received at least one intravenous dose of PIXCLARA at a mean activity of 155 ± 53.5 MBq (4.2 ± 1.4 mCi).

The mean age of the patients was 57 years (range: 5 years to 86 years). Sex was 59% male, 37% female, and 3% unreported. Distribution by race was 26% White, 6% Asian, <1% Black or African American, and 67% other or unreported. Distribution by ethnicity was 3% Hispanic/Latino, 96% non-Hispanic/Latino, and <1% unknown or unreported.

Adverse reactions that occurred in ≥0.5% of patients receiving PIXCLARA were headache (0.5%).

Adverse reactions that occurred in <0.5% of patients were nausea, injection site reaction, fatigue, and malaise.

Adverse Reactions in Pediatric Patients

Overall, the safety profile observed in pediatric patients from the clinical study was consistent with the safety profile in adult patients.

Please note that this information is not comprehensive.
Please see the Full Prescribing Information at https://telixpharma.com/pixclara-uspi

You are encouraged to report suspected adverse reactions of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report adverse reactions to Telix Pharmaceuticals (US) by calling 1-844-455-8638 or emailing pharmacovigilance@telixpharma.com.

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease.

Telix’s commercial franchise is anchored by its precision diagnostics portfolio: Illuccix® (kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries including the U.S., and Gozellix® (kit for the preparation of gallium-68 gozetotide injection), approved by the U.S. Food and Drug Administration (FDA) for prostate imaging, and Pixclara® (floretyrosine F18) approved by the FDA for glioma imaging. The Company’s late-stage therapeutic pipeline includes three investigational assets in pivotal-stage trials: TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) in prostate cancer, TLX101-Tx (131I-iodofalan) in recurrent glioblastoma, and TLX250-Tx (lutetium (177Lu) girentuximab tetraxetan) in kidney cancer, additionally complemented by a deep pipeline of next generation candidates. TLX591-Tx, TLX101-Tx and TLX250-Tx have not received marketing authorizations in any jurisdiction.

Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific. For more information, visit www.telixpharma.com or follow Telix on LinkedIn, X and Facebook.

Investor Relations

Annie Kasparian
annie.kasparian@telixpharma.com

Charlene Jaw
charlene.jaw@telixpharma.com

Media

Eliza Schleifstein
917.763.8106 (Mobile)
eliza@schleifsteinpr.com

 
     

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

___________________
1 Galldiks et al. Lancet Oncol. 2025 (Joint guidelines from the European Association of Nuclear Medicine (EANM), European Association of Neuro-Oncology (EANO), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Response Assessment in Neuro-Oncology (RANO), The European Society for Pediatric Oncology and The Response Assessment in Pediatric Neuro-Oncology for the characterization of recurrence in glioma patients); National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers V3.2026.
2 Goodenberger et al. Cancer Genet. 2012.
3 CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2018-2022. Neuro-Oncology. 2025.
4 Investigational New Drug (IND) application successfully cleared, with Study May Proceed notification received from FDA. Telix ASX disclosure August 20, 2026.

Key Takeaways:

  • Parsons secured nine “Awardable” designations across two leading Department of War digital marketplaces designed to rapidly deploy operational capabilities to warfighters at the edge.
  • Three solutions were recognized in Platform One and six in Tradewinds, expanding Parsons’ presence across the defense technology ecosystem.
  • The designations enable faster evaluation, procurement, and deployment of innovative mission-focused capabilities.

CHANTILLY, Va., Sept. 14, 2026 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) announced today that nine of its digital solutions have been designated as “Awardable” across leading Department of War (DoW) digital marketplaces, accelerating government access to proven, mission-ready technologies.

For decades, Parsons has delivered innovative, rapid solutions to national security challenges that face the United States and its allies.

“Having nine Parsons solutions designated as ‘Awardable’ demonstrates the depth and maturity of our mission-ready defense product portfolio and reinforces our ability to deliver innovative capabilities that address our customers’ most critical national security challenges,” said Aaron Wajsgras, vice president of product strategy & commercialization for Parsons. “This achievement validates the mission impact of our products while meeting the Department of War’s mission requirements of faster and easier acquisition and deployment in support of critical national security priorities.”

Tradewinds Solutions Marketplace

Six Parsons solutions are designated “Awardable” in the Tradewinds Solutions Marketplace, a Department of War marketplace designed to accelerate the procurement and adoption of innovative commercial technologies through streamlined acquisition pathways. Parsons’ awardable solutions on Tradewinds include Ground Operations Command as a Service (GOCaaS), OrbitXchange™, SPARTAN Antenna, DroneArmor™, C2Core® Air, and Assured Positioning System (APS™).

  • GOCaaS is a cloud-native satellite operations platform that provides automated commanding, telemetry analysis, orbit determination, maneuver planning, mission data delivery, and constellation management for any satellite, in any orbit, and any constellation size.
  • OrbitXchange™ is an automated, cloud-native, cybersecure satellite communications solution that leverages commercial antenna networks to provide flexible, scalable, automated, and operationally proven ground station access.
  • SPARTAN Antenna is an advanced phased-array-fed parabolic antenna system that enables simultaneous satellite commanding, telemetry, and mission data collection for up to eight spacecraft simultaneously through electronically steerable beams.
  • DroneArmor™ is a fully automated counter-unmanned aircraft system (C-UAS) command-and-control platform that integrates sensors, effectors, and AI-enabled software to provide real-time drone threat detection, tracking, and response capabilities.
  • C2Core® Air is a cloud-native command and control solution that enables end-to-end air operations planning, tasking, execution monitoring, and combat assessment within a distributed operating environment. Using the Strategy through Assessment workflow developed for C2Core, C2Core Air provides seamless integration of strategic, operational, and tactical levels of planning and mission management.
  • APS™ provides resilient positioning, navigation, and timing (PNT) information when GPS or other global navigation satellite systems (GNSS) are jammed, spoofed, or otherwise unavailable or unreliable. APS uses proprietary satellite-based hybrid technology to produce reliable PNT data from non-GPS/non-GNSS RF transmissions from commercial and non-commercial communications satellites, including low-Earth orbit (LEO) vehicles. With APS, critical terrestrial and airborne applications that rely on PNT can continue to operate and execute their missions when GPS is undependable or unavailable.

The inclusion of these products in the Tradewinds Solutions Marketplace makes it easier for defense customers to rapidly identify, evaluate, and acquire trusted technologies that address evolving mission requirements.

Platform One Solutions Marketplace

Three Parsons solutions are designated “Awardable” in the Platform One Solutions Marketplace, one of DoW’s premier technology environments for discovering, evaluating, and rapidly acquiring vetted software capabilities. Sponsored by the U.S. Air Force, Platform One features post-competition solutions that enable organizations to identify and field mission-ready technologies. Parsons’ awardable solutions on Platform One include its Modern Extract, Transform, and Load (METAL) software application development approach, Support Velocity Helpdesk Automation solution, and TReX signal and channel emulation solution.

  • METAL is a modern application development approach designed to handle large and complex data workloads, integrate diverse data sources, and provide resilient, scalable architectures using containerization, microservices, and Kubernetes.
  • Support Velocity is an information technology service management (ITSM) solution that uses artificial intelligence (AI) and machine learning (ML) to categorize help desk tickets, reducing technician workload and improving resolution times.
  • TReX is a software- and commercial off-the-shelf hardware-based signal and channel emulation solution that enables realistic electronic warfare testing, evaluation, and warfighter training using representative signals of interest.

The availability of these products on the Platform One Solutions Marketplace enables defense customers to rapidly identify, evaluate, and acquire mission-ready software and technology solutions.

For more information about Parsons awardable solutions on the defense marketplace, visit: Awardable Defense Marketplace Solutions | Parsons Corporation

About Parsons:
Parsons (NYSE: PSN) is a leading disruptive technology provider in the national security and global infrastructure markets, with capabilities across cyber and electronic warfare, space and missile defense, transportation, water and environment, urban development, and critical infrastructure protection. Please visit Parsons.com and follow us on LinkedIn to learn how we’re making an impact.

Forward-Looking Statements:
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on our current expectations, beliefs and assumptions, and are not guarantees of future performance. Forward-looking statements are inherently subject to uncertainties, risks, changes in circumstances, trends and factors that are difficult to predict, many of which are outside of our control. Accordingly, actual performance, results and events may vary materially from those indicated in the forward-looking statements, and you should not rely on the forward-looking statements as predictions of future performance, results or events. Numerous factors could cause actual future performance, results and events to differ materially from those indicated in the forward-looking statements, including, among others: any issue that compromises our relationships with the U.S. federal government or its agencies or other state, local or foreign governments or agencies; any issues that damage our professional reputation; changes in governmental priorities that shift expenditures away from agencies or programs that we support; our dependence on long-term government contracts, which are subject to the government’s budgetary approval process; the size of our addressable markets and the amount of government spending on private contractors; failure by us or our employees to obtain and maintain necessary security clearances or certifications; failure to comply with numerous laws and regulations; changes in government procurement, contract or other practices or the adoption by governments of new laws, rules, regulations and programs in a manner adverse to us; the termination or nonrenewal of our government contracts, particularly our contracts with the U.S. federal government; our ability to compete effectively in the competitive bidding process and delays, contract terminations or cancellations caused by competitors’ protests of major contract awards received by us; our ability to generate revenue under certain of our contracts; any inability to attract, train or retain employees with the requisite skills, experience and security clearances; the loss of members of senior management or failure to develop new leaders; misconduct or other improper activities from our employees or subcontractors; our ability to realize the full value of our backlog and the timing of our receipt of revenue under contracts included in backlog; changes in the mix of our contracts and our ability to accurately estimate or otherwise recover expenses, time and resources for our contracts; changes in estimates used in recognizing revenue; internal system or service failures and security breaches; and inherent uncertainties and potential adverse developments in legal proceedings, including litigation, audits, reviews and investigations, which may result in materially adverse judgments, settlements or other unfavorable outcomes. These factors are not exhaustive and additional factors could adversely affect our business and financial performance. For a discussion of additional factors that could materially adversely affect our business and financial performance, see the factors included under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and our other filings with the Securities and Exchange Commission. All forward-looking statements are based on currently available information and speak only as of the date on which they are made. We assume no obligation to update any forward-looking statement made in this press release that becomes untrue because of subsequent events, new information or otherwise, except to the extent we are required to do so by law.

Media Contact:                                        
Bernadette Miller
+1 980.253.9781
bernadette.miller@parsons.com

Investor Relations Contact:
Dave Spille
+1 703.775.6191
Dave.Spille@parsons.us

Enhanced rail-pressure control, improved durability and more adaptable architecture deliver greater performance and integration flexibility, strengthening the case for broader adoption by OEMs and operators worldwide

VANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) — Westport Fuel Systems Inc. (“Westport”) (TSX:WPRT / Nasdaq: WPRT), today announced Cespira, its joint venture with Volvo Group, released new technical details of HPDI™ 3.0, the next generation of its proven High Pressure Direct Injection fuel system.

HPDI 3.0 retains proven HPDI combustion principles while advancing fuel rail-pressure control, hardware durability and system integration. The new fuel system supports liquefied natural gas (LNG) and renewable bio-based liquefied natural gas (bioLNG) today while preserving adaptability for future low- and zero-carbon fuels.

Performance Enhancements
At its core, HPDI 3.0 incorporates a new fuel rail-pressure control architecture that improves fuel economy and engine performance while simplifying OEM calibration. Higher injection pressure capability unlocks greater power and efficiency from the latest high-performance compression-ignition engines, while the architecture is designed to support compliance with future global emissions regulations.

Improved Durability and Greater Integration Flexibility
The new hardware integrates proven HPDI injector dynamic sealing technology to enhance component service life. A modular fuel rail-pressure control architecture gives OEMs greater packaging flexibility across different engine layouts. The new system supports larger engines, including V12 and other multi-bank configurations, by allowing fuel pressure control across separate cylinder banks. This broadens the potential application of HPDI 3.0 across demanding on-road and off-road sectors.

Built for Natural Gas and Biogas Today, Adaptable for Future Fuels
HPDI 3.0 reinforces the near-term value of natural gas and renewable natural gas for heavy-duty transport by enabling the use of LNG and bioLNG with diesel-like performance, improved efficiency and attractive total cost of ownership. The architecture also maintains a clear pathway for future fuel-specific applications, including hydrogen, as those markets develop.

“Cespira’s revenue increased 125% year over year from Q2 2025 to Q2 2026, underscoring strong market validation for HPDI technology. With continued gains in efficiency, attractive total cost of ownership and improved fuel price stability, we believe HPDI is well positioned to grow adoption momentum with OEMs and fleets,” said Dan Sceli, Chief Executive Officer of Westport.

“HPDI 3.0 strengthens both the immediate and long-term business case for OEMs. More precise fuel rail pressure control, higher injection pressure capability, enhanced durability and improved fuel economy make HPDI 3.0 a more compelling proposition for LNG and BioLNG applications. The architecture is also more readily adaptable to future fuel-specific systems for hydrogen and low-carbon fuels, giving OEMs greater flexibility to build on their HPDI investment and expand their product portfolios as those fuel markets develop,” said Scott Baker, CTO of Cespira.

HPDI 3.0 builds on a proven technology foundation, with the current generation accumulating more than 3 billion kilometers of real-world operation across 12,000+ trucks in over 35 countries. Cespira will begin production of HPDI 3.0 in the fourth quarter of 2026, with the first HPDI 3.0 equipped vehicles expected on the road in early 2027.

More information about Cespira can be found at www.Cespira.com.

About Westport

Westport is a technology and innovation company connecting synergistic technologies to power a cleaner tomorrow. As a leading supplier of affordable, alternative fuel, low-emissions transportation technologies, we design, manufacture, and supply advanced components and systems that enable the transition from traditional fuels to cleaner energy solutions.

Our proven technologies support a wide range of alternative fuels – including natural gas, renewable natural gas, and hydrogen – empowering OEMs and commercial transportation industries to meet performance demands, regulatory requirements, and climate targets in a cost-effective way. With decades of expertise and a commitment to engineering excellence, Westport is helping our partners achieve sustainability goals-without compromising performance or cost-efficiency – making clean, scalable transport solutions a reality.

Westport is headquartered in Vancouver, Canada.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding, among other things, the anticipated performance, efficiency and emissions characteristics of Cespira’s HPDI™3.0 fuel system; the timing for commencement of production for HPDI 3.0 equipped vehicles and for such vehicles to be in operation; and the intentions, plans and actions of our joint venture and other partners. Forward-looking statements are based on management’s current expectations and assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. These risks, uncertainties and assumptions include, among others: the ability of Westport, Cespira and their partners to successfully develop, integrate, validate, and certify HPDI technology on expected timelines or at all; the results of testing and development activities and the ability to achieve required performance, durability, reliability, safety and regulatory requirements; the receipt and timing of required regulatory approvals, certifications and homologation, changes in laws, regulations and standards and incentive programs applicable to emissions, engine certification and vehicle classification; competitive technologies and products; general economic and market conditions; as well as other risk factors, uncertainties and assumptions that may affect our actual results, performance, achievements or financial position discussed in our most recent Annual Information Form and other filings with securities regulators. Readers should not place undue reliance on any such forward-looking statements, which speak only as of the date they were made. We disclaim any obligation to publicly update or revise such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in these forward looking statements except as required by National Instrument 51-102. The contents of any website, RSS feed or twitter account referenced in this press release are not incorporated by reference herein.

Contact Information
Westport Investor Relations
T: +1 604-718-2046

TORONTO, Sept. 14, 2026 (GLOBE NEWSWIRE) — TRX Gold Corporation (TSX: TRX) (NYSE American: TRX) (the “Company” or “TRX Gold”) is pleased to report that the Company has been added to the MVIS® Global Junior Gold Miners Index (“MVGDXJ”) following the Q3 2026 index rebalance announcement on September 11, 2026.

Stephen Mullowney, TRX Gold CEO commented: “Following our addition to the S&P/TSX Global Mining Index announced on March 28, I am very pleased to announce that TRX Gold has now also met the criteria for inclusion in the MVGDXJ, which is designed to track the overall performance of small-capitalization companies that are involved primarily in the mining of gold and/or silver1. TRX Gold’s inclusion in this major index has the potential to maintain and attract additional global institutional investment into the Company and increase liquidity, with the MVGDXJ being an important benchmark requirement for many large investment funds. This addition also positions the Company for possible inclusion in related funds and ETFs, including the Van Eck Junior Gold Miners ETF (“GDXJ®”) which seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVGDXJ. Congratulations to the entire team on achieving this important milestone!”

For the MVIS Global Junior Gold Miners Index (MVGDXJ), the Q3 2026 rebalance schedule is as follows:

  • Index data / reference date: August 31, 2026
  • Rebalance announcement: September 11, 2026
  • Index Implementation / rebalance date: September 18, 2026
  • New composition becomes effective: September 21, 2026, the next trading day after implementation.

About MVGDXJ1
The MVIS® Global Junior Gold Miners Index (MVGDXJ) tracks the performance of the most liquid small-cap companies in the global gold and silver mining industries. This is a modified market cap-weighted index, and only includes companies that generate at least 50% of their revenue from gold or silver mining, or at least 50% of their mining mineral resources are from gold or silver. For more information about the MVIS® Global Junior Gold Miners Index, please visit the index provider’s website.

1Source: https://www.marketvector.com/indexes/hard-asset/mvis-global-junior-gold-miners

About TRX Gold Corporation

TRX Gold is a high margin and growing gold company advancing the Buckreef Gold Project in Tanzania. Buckreef Gold includes an established open pit operation and 2,000 tonnes per day process plant with upside potential demonstrated in the May 2025 Preliminary Economic Assessment (the “PEA”). The PEA outlines average gold production of 62,000 oz per annum over 17.6 years at 3,000 tonnes per day of throughput capacity, and a US$1.9 –US$2.6 billion pre-tax NPV5% at average life of mine gold prices of US$4,000-US$5,000/oz. The Buckreef Gold Project hosts a Measured and Indicated Mineral Resource of 10.8 million tonnes (“MT”) at 2.57 grams per tonne (“g/t”) gold containing 893,000 ounces (“oz”) of gold and an Inferred Mineral Resource of 9.1 MT at 2.47 g/t gold for 726,000 oz of gold. The leadership team is focused on creating both near-term and long-term shareholder value by increasing gold production to generate positive cash flow to fund the expansion as outlined in the PEA and grow Mineral Resources through exploration. TRX Gold’s actions are led by the highest environmental, social and corporate governance (“ESG”) standards, evidenced by the relationships and programs that the Company has developed during its nearly two decades of presence in the Geita Region, Tanzania.

Qualified Person

Mr. Richard Boffey, BE Mining (Hons) F AusIMM, Chief Operating Officer of TRX Gold Corporation, is the Company’s in-house Qualified Person under National Instrument 43-101 “Standards of Disclosure for Mineral Projects” (“NI 43-101”) and has reviewed and assumes responsibility for the scientific and technical content in this press release.

For investor or shareholder inquiries, please contact:

Investor Relations
IR@TRXgold.com
+1-437-224-5241
+1 844 GOLD TRX (844-465-3879)
www.TRXgold.com

Forward-Looking and Cautionary Statements

This press release contains certain forward-looking statements as defined in the applicable securities laws. All statements, other than statements of historical facts, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “hopes”, “intends”, “estimated”, “potential”, “possible” and similar expressions, or statements that events, conditions or results “will”, “may”, “could” or “should” occur or be achieved. Forward-looking statements relate to future events or future performance and reflect TRX Gold management’s expectations or beliefs regarding future events and include, but are not limited to, statements with respect to future inclusion of TRX Gold in additional indices or funds, ability to attract investors or increase liquidity as a result of being included in any index or for any other reason, future gold prices, continued operating cash flow, expansion of its process plant, estimation of mineral resources, ability to develop value creating activities, recoveries, subsequent project testing, success, scope and viability of mining operations, the timing and amount of estimated future production and capital expenditures.

Although TRX Gold believes the expectations expressed in such forward-looking statements and the preliminary data included in this press release are based on reasonable assumptions, such statements are not guarantees of future performance. The actual achievements of TRX Gold or other future events or conditions may differ materially from those reflected in the preliminary data and forward-looking statements due to a variety of risks, uncertainties and other factors. These risks, uncertainties and factors include general business, legal, economic, competitive, political, regulatory and social uncertainties; actual results from operations, exploration activities and economic evaluations; fluctuations in currency exchange rates; changes in costs; future prices of gold and other minerals; mining method, production profile and mine plan; delays in exploration, development and construction activities; changes in government legislation and regulation; the ability to obtain financing on acceptable terms and in a timely manner or at all; contests over title to properties; employee relations and shortages of skilled personnel and contractors; the speculative nature of, and the risks involved in, the exploration, development and mining business. These risks are set forth in reports that TRX Gold files with the SEC and the various Canadian securities authorities. You can review and obtain copies of these filings from the SEC’s website at http://www.sec.gov/edgar.shtml and the Company’s profile on the System for Electronic Document Analysis and Retrieval (“SEDAR+”) at www.sedarplus.ca.

The disclosure contained in this press release of a scientific or technical nature relating to the Company’s Buckreef Project has been summarized or extracted from the technical report prepared in accordance with NI 43-101 – Standards of Disclosure for Mineral Projects on the Buckreef Gold Project (“Buckreef Gold”) titled Preliminary Economic Assessment and Updated Mineral Resource Estimate of the Buckreef Gold Mine Project, Tanzania (“PEA”) with an effective date of April 15, 2025. The PEA was prepared in accordance with NI 43-101 guidelines by P&E Mining Consultants Inc. (“P&E”). Input to this PEA was also provided by D.E.N.M. Engineering Ltd. (“D.E.N.M.”). The information contained herein is subject to all of the assumptions, qualifications and procedures set out in, and is qualified in its entirety by reference to the full text of, the PEA and reference should be made to the full details of the PEA which has been filed with the applicable regulatory authorities and is available on the Company’s profile at www.sedarplus.ca.

The information contained in this press release is as of the date of the press release and TRX Gold assumes no duty to update such information.

SEATTLE, Sept. 14, 2026 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced a clinical trial collaboration agreement with Merck (NYSE: MRK), known as MSD outside of the United States and Canada.

The agreement supports the evaluation of Perspective’s targeted alpha-particle therapy [212Pb]PSV359 in combination with Keytruda® (pembrolizumab), Merck’s anti-PD-1 therapy. This combination will be evaluated under an amendment to the Company’s ongoing Phase 1/2a study of [212Pb]PSV359 in patients with certain types of non-small cell lung cancer and colorectal cancer that express fibroblast activation protein alpha (FAP-α) (clinicaltrials.gov identifier NCT06710756). The study has completed enrollment in the first three monotherapy dose cohorts.

Perspective is sponsoring the study, and Merck is providing pembrolizumab at no cost.

“FAP-α is associated with the majority of solid tumors and with a tumor microenvironment historically characterized by poor drug penetration and immune suppression or exclusion,” said Markus Puhlmann, Perspective’s Chief Medical Officer. “By combining targeted radiopharmaceutical treatment with a well-established immune checkpoint inhibitor, we aim to evaluate whether this approach can reshape the tumor environment and potentially improve treatment outcomes for patients with advanced FAP-α-positive solid tumors.”

About FAP-α

FAP-α is a protein abundantly expressed on the surface of cancer-associated fibroblasts (CAFs) in the stroma, a part of the tumor microenvironment (TME) in the majority of epithelial cancers. In addition to expression on CAFs, FAP-α is expressed on certain cancer cells themselves, including sarcomas and mesotheliomas.1,2,3,4 Higher FAP-α expression has been found to be associated with poor prognosis in a number of solid tumors such as non-small cell lung cancer, colorectal cancer, pancreatic cancer, stomach cancer, mesothelioma, head and neck cancer, esophageal cancer, and ovarian cancer.5,6,7,8,9,10 Expression of FAP-α in healthy tissues is usually low.3,4

About PSV359

PSV359 was designed to target and deliver 212Pb to tumor sites expressing FAP-α, associated with multiple highly prevalent solid tumors, with patients in need of additional treatment options. The targeting moiety may also be radiolabeled with 203Pb or 68Ga (known as PSV377) to detect FAP-α expression in individual patients. Preclinical imaging and therapy as well as human imaging results suggest Perspective’s proprietary targeting ligand has improved levels of target engagement and uptake in tumors, as well as reduced retention in healthy tissues, which may result in a desirable therapeutic index.

Perspective is conducting a multi-center, open-label, dose-finding and dose-expansion study (clinicaltrials.gov identifier NCT06710756) of [212Pb]PSV359 in patients with advanced solid tumors that express FAP-α as determined by imaging with [203Pb]PSV359. The primary objective of the dose finding phase of the study is to assess the safety and tolerability of various doses of [212Pb]PSV359 in order to determine the recommended Phase 2 dose to be used in the expansion phase of the study, where anti-tumor activities may be an additional primary outcome measure.

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-generating isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This “theranostic” approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity.

The Company is advancing a portfolio of clinical-stage programs in the U.S., including bamzireotide navoxetan (VMT-α-NET, neuroendocrine tumors), lapemelanotide zapixetar (VMT01, melanoma), and PSV359 (solid tumors).

The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary 224Ra/212Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candidates for clinical trials and, if approved, commercial operations.

For more information, please visit the Company’s website at www.perspectivetherapeutics.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential,” or “continue” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company’s preclinical and clinical development plans and the expected timing for the release of additional data from its clinical programs; the Company’s beliefs that its product candidates address certain unmet medical needs; the Company’s expectations regarding regulatory pathways for its product candidates; the Company’s expectations regarding its interactions with regulatory agencies and the expected timing thereof; the Company’s regional distribution and manufacturing capabilities; and other statements that are not historical fact.

The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company’s actual results to differ materially from the results described in or implied by the forward-looking statements. Known risk factors include that the Company’s clinical trials may be more costly or take longer to complete than anticipated, or may never be completed, or may not generate results that warrant future development of the tested product candidate; the Company may elect to change its strategy regarding its product candidates and clinical development activities; economic and market conditions may worsen; and risks related to the sufficiency of the Company’s cash resources for its future operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), in the Company’s other filings with the SEC, and in the Company’s future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Media and Investor Relations Contacts:

Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com

ENTENTE Network of Companies
Katie Morris, PhD
katiemorris@ententeinc.com


1 Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A. 1990;87(18):7235-7239. doi:10.1073/pnas.87.18.7235
2 Dziadek S, Kraxner A, Cheng WY, et al. Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies. Front Immunol. 2024;15:1352615. Published 2024 Mar 15. doi:10.3389/fimmu.2024.1352615
3 Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med. 2019;60(6):801-805. doi:10.2967/jnumed.119.227967
4 Fitzgerald AA, Weiner LM. The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev. 2020;39(3):783-803. doi:10.1007/s10555-020-09909-3
5 Cords L, Engler S, Haberecker M, et al. Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer. Cancer Cell. 2024;42(3):396-412.e5. doi:10.1016/j.ccell.2023.12.021
6 Coto-Llerena M, Ercan C, Kancherla V, et al. High Expression of FAP in Colorectal Cancer Is Associated With Angiogenesis and Immunoregulation Processes. Front Oncol. 2020;10:979. Published 2020 Jul 8. doi:10.3389/fonc.2020.00979
7 Henry LR, Lee HO, Lee JS, et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res. 2007;13(6):1736-1741. doi:10.1158/1078-0432.CCR-06-1746
8 Wang S, Zheng Y, Yang F, et al. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Signal Transduct Target Ther. 2021;6(1):249. Published 2021 Jul 5. doi:10.1038/s41392-021-00659-4
9 Cohen SJ, Alpaugh RK, Palazzo I, et al. Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas. 2008;37(2):154-158. doi:10.1097/MPA.0b013e31816618ce
10 Ma C, Xi S, Sun, H, et al. Identifying the oncogenic roles of FAP in human cancers based on systematic analysis. Aging 2023;15(14):7056-7083. doi: 10.18632/aging.204892

TR-1: Standard form for notification of major holdings

01.  Issuer Details

ISIN            

GB00BLDRH360

Issuer Name    

OSB GROUP PLC

UK or Non-UK Issuer   

UK

02. Reason for Notification

      An acquisition or disposal of voting rights

03. Details of person subject to the notification obligation

Name

Lorentzweiler Adjacent Partners S.C.Sp

City of registered office (if applicable)

Howald

Country of registered office (if applicable)

Luxembourg

04. Details of the sharholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

City of registered office (if applicable)

Country of registered office (if applicable)

05. Date on which the threshold was crossed or reached

      09-Sep-2026

06. Date on which Issuer notified

     11-Sep-2026

07. Total positions of person(s) subject to the notification obligation

  % of voting rights attached % of voting rights through financial Total of both in % (8.A + 8.B) Total number of voting rights held in issuer

  to shares (total of 8.A) instruments (total of 8.B 1 + 8.B 2)    
Resulting situation on the date on which threshold was crossed or reached

4.019900

0.000000

4.019900

13637487

Position of previous notification (if applicable)

3.096900

0.000000

3.096900

 

08. Notified details of the resulting situation on the date on which the threshold was crossed or reached

08A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible) Number of direct voting rights (DTR5.1) Number of indirect voting rights (DTR5.2.1) % of direct voting rights (DTR5.1) % of indirect voting rights (DTR5.2.1)
GB00BLDRH360 13637487 0 4.019900 0.000000
Sub Total 8.A 13637487 4.019900%

08B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument Expiration date Exercise/conversion period Number of voting rights that may be acquired if the instrument is exercised/converted % of voting rights
Sub Total 8.B1      

08B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument Expiration date Exercise/conversion period Physical or cash settlement Number of voting rights % of voting rights
Sub Total 8.B2      

09. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the % of voting rights through financial instruments if it equals or is Total of both if it equals or is higher than the notifiable threshold

    notifiable threshold higher than the
notifiable threshold
 
Alan Waxman   3.096900   3.096900%

Alan Waxman

Sixth Street Partners Management Company, L.P.

3.096900

 

    3.096900%

Alan Waxman TAO Finance 3, LLC 1.858100   1.858100%
Alan Waxman Beacon Finance 3, LLC 0.619400   0.619400%

Alan Waxman

Sixth Street Madrone Strategic Holdings I, L.P

0.619400

 

    0.619400%

Alan Waxman

Lorentzweiler Adjacent Partners, S.C.Sp (acting through its general partner, Lorentzweiler Adjacent Investments, S.à r.l.)

3.096900

 

    3.096900%

Alan Waxman   4.019900   4.019900%

Alan Waxman

Sixth Street Partners Management Company, L.P.

4.019900

 

    4.019900%

Alan Waxman TAO Finance 3, LLC 2.411900   2.411900%
Alan Waxman Beacon Finance 3, LLC 0.804000   0.804000%

Alan Waxman

Sixth Street Madrone Strategic Holdings I, L.P

0.804000

 

    0.804000%

Alan Waxman

Lorentzweiler Adjacent Partners, S.C.Sp (acting through its general partner, Lorentzweiler Adjacent Investments, S.à r.l.)

4.019900

 

    4.019900%

  10. In case of proxy voting        

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

If date does not apply, explain below

11.    Additional Information        

        Correcting notification – UK Issuer

12.    Date of Completion        

               11-Sep-2026

13.    Place Of Completion        

        Luxembourg

TORONTO, Sept. 14, 2026 (GLOBE NEWSWIRE) — TRX Gold Corporation (TSX: TRX) (NYSE American: TRX) (the “Company” or “TRX Gold”) is pleased to announce preliminary results for Q4 20261.

  • Record Fourth Quarter Results Lead to Achieving Top End of Fiscal 2026 Production Guidance: In Q4 2026, the Company delivered record quarterly gold production of 8,173 ounces, up 28% from 6,404 ounces in Q4 2025. On a full year basis, the Company delivered record annual gold production of 29,650 ounces, an increase of 57% from 18,935 ounces in 2025, and achieved the top end of its full-year production guidance range of 25,000 to 30,000 ounces.
  • Record Gold Price Realization: During Q4 2026, the Company benefited from a robust average market price for gold of approximately $4,233 per ounce (London PM fix), a 26% increase over the prior year comparative period (Q4 2025: $3,369 per ounce). Combined with higher year over year production, revenue is expected to be significantly higher in Q4 2026 than in the prior year comparative period. On a full year basis, the Company benefited from a record annual average market price for gold of approximately $4,386 per ounce (London PM fix), a 46% increase over the prior year comparative period (2025: $2,999 per ounce). On a full year basis, revenue is expected to be significantly higher in 2026 than in 2025.
  • Process Plant Upgrades Lead to Improved Throughput, Recovery and Gold Production: During Q4 2026 the Company continued to make progress on upgrades to the existing 2,000 tpd processing plant. Notable upgrades to the existing processing plant include a pre-leach thickener, upgraded agitators & interstage screens, Aachen reactor, oxygen plant, Adsorption, Desorption and Recovery (“ADR”) plant, new gold room, apron feeder, belt magnet, and new tertiary crusher. The plant upgrades are in various stages of completion and have already begun to boost plant reliability and performance as evidenced by an increase in plant throughput, gold recovery and gold production in Q4 2026 versus the prior year comparative period.
  • Advancing Process Plant Expansion to Significantly Increase Future Production Capacity: The Company continues to advance its processing plant expansion, a key catalyst for future growth. As previously reported, recent metallurgical test work has led the Company to specify a Semi Autogenous Grind (“SAG”) / Ball mill combination of 3,500 tpd as part of its next processing plant expansion based on optimal grind size for achievable mine feed from the mine plan. Final contract execution for the new SAG / Ball mill was completed in early Q4 2026, initial downpayments have been made, and estimated completion is expected over the next 12 – 18 months. The existing, upgraded 2,000 tpd processing plant will be available to continue operating in conjunction with the new 3,500 tpd SAG / Ball mill processing plant, providing a significant upgrade in processing capacity versus the 3,000 tpd assumed in the PEA. The increase in throughput from the expanded processing plant is expected to produce average annual gold production in excess of the 62,000 ounces of gold originally anticipated in the PEA.
  • Exploration to Ramp-Up Significantly: During fiscal 2026, Buckreef Gold drilled approximately 175 drill holes for a total of 14,500 meters across resource definition, geotechnical, sterilization and greenfield exploration. This was predominantly completed in the second half of fiscal 2026 utilizing one Company owned reverse circulation (“RC”) drill rig and one contractor diamond drill (“DD”) rig. The RC drill rig was commissioned in March 2026 and the DD rig in April 2026. Buckreef Gold also utilized the RC drill rig for ongoing grade control drilling for normal course operations. Buckreef Gold has also purchased: (i) an additional DD drill rig which is currently onsite and being commissioned; (ii) a new RC drill rig which is expected to be onsite in the next 2-4 weeks; and (iii) a new RC/DD combination drill rig which is expected to arrive in the next 4-6 months. These purchases in combination with existing drill rigs on site will significantly increase Buckreef Gold’s drilling capacity and will be utilized for grade control, resource definition, geotechnical, sterilization and greenfield exploration drilling. Given the significant increase in drilling capacity, there will be a significant increase in greenfield exploration, including: (i) the anomalies from the comprehensive geophysics study which identified ten promising targets; and (ii) Stamford Bridge and the Anfield Zone.

Stephen Mullowney, TRX Gold CEO commented: “We are very pleased to have delivered record quarterly and annual gold production in fiscal 2026, achieving the top end of our production guidance while continuing to improve the performance and reliability of our processing plant. The combination of higher production, a robust gold price environment and a strong balance sheet positions us well as we continue to build momentum across the business. Our accelerated plant expansion is laying the foundation for the next stage of growth at Buckreef Gold. The addition of a 3,500 tpd SAG/Ball mill circuit, together with significant upgrades to our existing 2,000 tpd plant, will provide combined processing capacity well beyond the 3,000 tpd capacity contemplated in our PEA last year, unlocking significant value. The improvements we have already made to the existing plant are contributing to higher throughput, recovery and production, while the new SAG/Ball mill represents a significant step forward in our ability to support significantly higher gold production in the years ahead. With a strong balance sheet and a clear path to increased production, we are well positioned to execute on our growth plans and create long-term value for our shareholders.”

About TRX Gold Corporation

TRX Gold is a high margin and growing gold company advancing the Buckreef Gold Project in Tanzania. Buckreef Gold includes an established open pit operation and 2,000 tonnes per day process plant with upside potential demonstrated in the May 2025 Preliminary Economic Assessment (the “PEA”). The PEA outlines average gold production of 62,000 oz per annum over 17.6 years at 3,000 tonnes per day of throughput capacity, and a US$1.9 –US$2.6 billion pre-tax NPV5% at average life of mine gold prices of US$4,000-US$5,000/oz2. The Buckreef Gold Project hosts a Measured and Indicated Mineral Resource of 10.8 million tonnes (“MT”) at 2.57 grams per tonne (“g/t”) gold containing 893,000 ounces (“oz”) of gold and an Inferred Mineral Resource of 9.1 MT at 2.47 g/t gold for 726,000 oz of gold. The leadership team is focused on creating both near-term and long-term shareholder value by increasing gold production to generate positive cash flow to fund the expansion as outlined in the PEA and grow Mineral Resources through exploration. TRX Gold’s actions are led by the highest environmental, social and corporate governance (“ESG”) standards, evidenced by the relationships and programs that the Company has developed during its nearly two decades of presence in the Geita Region, Tanzania.

Qualified Person

Mr. Richard Boffey, BE Mining (Hons) F AusIMM, Chief Operating Officer of TRX Gold Corporation, is the Company’s in-house Qualified Person under National Instrument 43-101 “Standards of Disclosure for Mineral Projects” (“NI 43-101”) and has reviewed and assumes responsibility for the scientific and technical content in this press release.

For investor or shareholder inquiries, please contact:

Investor Relations
IR@TRXgold.com
+1-437-224-5241
+1 844 GOLD TRX (844-465-3879)
www.TRXgold.com

Forward-Looking and Cautionary Statements

This press release contains certain forward-looking statements as defined in the applicable securities laws. All statements, other than statements of historical facts, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “hopes”, “intends”, “estimated”, “potential”, “possible” and similar expressions, or statements that events, conditions or results “will”, “may”, “could” or “should” occur or be achieved. Forward-looking statements relate to future events or future performance and reflect TRX Gold management’s expectations or beliefs regarding future events and include, but are not limited to, statements with respect to future gold prices, continued operating cash flow, expansion of its process plant, estimation of mineral resources, ability to develop value creating activities, recoveries, subsequent project testing, success, scope and viability of mining operations, the timing and amount of estimated future production, and capital expenditure.

Although TRX Gold believes the expectations expressed in such forward-looking statements and the preliminary data included in this press release are based on reasonable assumptions, such statements are not guarantees of future performance. The actual achievements of TRX Gold or other future events or conditions may differ materially from those reflected in the preliminary data and forward-looking statements due to a variety of risks, uncertainties and other factors. These risks, uncertainties and factors include general business, legal, economic, competitive, political, regulatory and social uncertainties; actual results from operations, exploration activities and economic evaluations; fluctuations in currency exchange rates; changes in costs; future prices of gold and other minerals; mining method, production profile and mine plan; delays in exploration, development and construction activities; changes in government legislation and regulation; the ability to obtain financing on acceptable terms and in a timely manner or at all; contests over title to properties; employee relations and shortages of skilled personnel and contractors; the speculative nature of, and the risks involved in, the exploration, development and mining business. These risks are set forth in reports that TRX Gold files with the SEC and the various Canadian securities authorities. You can review and obtain copies of these filings from the SEC’s website at http://www.sec.gov/edgar.shtml and the Company’s profile on the System for Electronic Document Analysis and Retrieval (“SEDAR+”) at www.sedarplus.ca.

The disclosure contained in this press release of a scientific or technical nature relating to the Company’s Buckreef Project has been summarized or extracted from the technical report prepared in accordance with NI 43-101 – Standards of Disclosure for Mineral Projects on the Buckreef Gold Project (“Buckreef Gold”) titled Preliminary Economic Assessment and Updated Mineral Resource Estimate of the Buckreef Gold Mine Project, Tanzania (“PEA”) with an effective date of April 15, 2025. The PEA was prepared in accordance with NI 43-101 guidelines by P&E Mining Consultants Inc. (“P&E”). Input to this PEA was also provided by D.E.N.M. Engineering Ltd. (“D.E.N.M.”). The information contained herein is subject to all of the assumptions, qualifications and procedures set out in, and is qualified in its entirety by reference to the full text of, the PEA and reference should be made to the full details of the PEA which has been filed with the applicable regulatory authorities and is available on the Company’s profile at www.sedarplus.ca. 

The information contained in this press release is as of the date of the press release and TRX Gold assumes no duty to update such information.


1 TRX Gold will provide additional discussion and analysis regarding its Q4 2026 production, sales and financial results when the Company reports its financial statements and Management’s Discussion and Analysis in November 2026. Financial figures quoted throughout are preliminary in nature, unaudited and subject to change.

2 Base case NPV5% of US$701.0 million pre-tax, or US$442.2 million after tax at consensus forecast case gold prices (US$2,707/oz year 1, US$2,646/oz year 2, US$2,495/oz year 3, US$2,400/oz year 4, US$2,245/oz thereafter).

ABB partners with Ferrari Hypersail

As Electrification Partner, ABB will support the development of Ferrari Hypersail's DC power architecture, building on more than 25 years of ABB leadership in DC technology and more than 700 patents.
As Electrification Partner, ABB will support the development of Ferrari Hypersail’s DC power architecture, building on more than 25 years of ABB leadership in DC technology and more than 700 patents.

Zurich, Switzerland, Sept. 14, 2026 (GLOBE NEWSWIRE) —

  • ABB partners with Ferrari Hypersail, an innovative 100-foot oceanic full-foiling monohull yacht powered by renewable energy systems
  • ABB’s 25+ years of DC technology leadership supports development of advanced 800 VDC power systems
  • ABB expertise will help maximize performance and resilience of onboard renewables in extreme ocean conditions

ABB today announces a technology partnership with Ferrari Hypersail that brings ABB’s electrification expertise to the world’s most ambitious offshore challenge. As Electrification Partner, ABB will support the challenge with expertise across marine power, Direct Current (DC) technology and advanced electrical systems.  

Ferrari Hypersail is a groundbreaking 100-foot oceanic full-foiling monohull yacht powered by renewable energy. The vessel is designed to push the boundaries of sustainable marine performance, bringing together speed, resilience and safety with onboard energy generation and management in one of the most technically demanding environments.  

ABB brings more than 25 years of experience in DC technology to the partnership, backed by a portfolio of more than 700 patents in the field. As Electrification Partner, ABB will support Ferrari Hypersail with expertise across energy management, marine electrical systems, energy storage and intelligent monitoring.  

Ferrari Hypersail provides ABB with a high-performance environment to demonstrate how advanced electrification, DC architectures and intelligent energy management can improve resilience and efficiency under extreme offshore conditions. These demands – balancing renewable generation, storage, monitoring and power distribution in real time – are critical to the development of next-generation industrial microgrids. 

“Ferrari Hypersail gives ABB a unique platform to demonstrate how we are collaborating with partners to push the limits of Direct Current technology,” said Giampiero Frisio, President of ABB’s Electrification business area. “Ferrari Hypersail is designed to operate in conditions that are as demanding as anything our systems face in industry. ABB’s role showcases how electrification and automation technologies help industries outrun and achieve record-breaking performance. The lessons from a challenge like this can help us advance the resilient, efficient power systems our customers need across sectors from marine and renewables to data centers and industrial microgrids.” 

For Enrico Voltolini, Project Leader of Ferrari Hypersail, the partnership delivers the technical foundation required to execute the mission. “Hypersail runs entirely on renewable energy,” Voltolini said. “It has to be self-sufficient for weeks at a time in the most hostile ocean environments on earth. Having ABB’s electrification expertise connected to the project is a valuable operational advantage.” 

Ferrari Hypersail’s DC architecture will function as a high-performance, self-sufficient microgrid with systems operating at 48V and 800 VDC. It will generate, store and manage power for critical navigation, foil controls, safety systems and propulsion while operating in conditions of extreme cold, salt spray, pressure and motion.  

ABB’s team will support Ferrari Hypersail with expertise in DC system integration, real-time monitoring, intelligent power distribution and resilience at sea. Insights from the project will help inform the development of advanced power systems for industries including shipping, data centers and renewable energy infrastructure.  

Further information:  
https://www.abb.com/global/en/company/about/engagements-and-partnerships/ferrari-hypersail 

About ABB 
ABB is a global technology leader in electrification and automation, enabling a more sustainable and resource-efficient future. By connecting its engineering and digitalization expertise, ABB helps industries run at high performance while becoming more efficient, productive and sustainable – what we call ‘Engineered to Outrun’. With over 140 years of history and approximately 110,000 employees worldwide, ABB is advancing electrification solutions across power generation, transmission, distribution, and consumption. ABB shares are listed on the SIX Swiss Exchange (ABBN) and Nasdaq Stockholm (ABB). www.abb.com 

Attachment

CONTACT: Sheela Pawar
ABB Electrification
sheela.pawar@ch.abb.com

   Heineken Holding N.V. reports transactions under its current share buyback programme

Amsterdam 14 September 2026 – Heineken Holding N.V. (EURONEXT:HEIO; OTCQX: HKHHY), hereby reports transaction details related to the second tranche of up to circa €375 million tranche of its share buyback programme of up to circa €750 million as communicated on 12 February 2026.

From 7 September 2026 up to and including 11 September 2026 a total of 169,918 shares were repurchased on exchange at an average price of €67.63.

Up to and including 11 September 2026, a total of 3,577,072 shares were repurchased under the second tranche of the share buyback programme for a total consideration of €234,321,209.

Heineken Holding N.V. publishes on a weekly basis, every Monday, an overview of the progress of the share buyback programme on its website: https://www.heinekenholding.com/investors/share-information/share-buyback-programme

Enquiries

Media Heineken Holding N.V.    
Kees Jongsma    
tel. +31 6 54 79 82 53    
E-mail: cjongsma@spj.nl

 

   
     
Media   Investors
Christiaan Prins   Tristan van Strien
Director of Global Communications   Global Director of Investor Relations
Marlie Paauw   Lennart Scholtus / Chris Steyn
Global Media Lead   Investor Relations Manager / Senior Analyst
E-mail: pressoffice@heineken.com   E-mail: investors@heineken.com
Tel: +31-20-5239355   Tel: +31-20-5239590

Regulatory information:
This press release is issued in connection with the disclosure and reporting obligations as set out in Article 5(1)(b) Regulation (EU) 596/2014 and Article 2(2) of the Commission Delegated Regulation (EU) 2016/1052 that contains technical standards for buyback programs.

Editorial information:
Heineken Holding N.V. engages in no activities other than its participating interest in Heineken N.V. and the management or supervision of and provision of services to that company. HEINEKEN is the world’s pioneering beer company. It is the leading developer and marketer of premium and non-alcoholic beer and cider brands. Led by the Heineken® brand, the Group has a portfolio of more than 340 international, regional, local and specialty beers and ciders. With HEINEKEN’s over 85,000 employees, HEINEKEN brews the joy of true togetherness to inspire a better world. HEINEKEN’s dream is to shape the future of beer and beyond to win the hearts of consumers. HEINEKEN is committed to innovation, long-term brand investment, disciplined sales execution and focused cost management. Through “Brew a Better World”, sustainability is embedded in the business. HEINEKEN has a well-balanced geographic footprint with leadership positions in both developed and developing markets. HEINEKEN operates breweries, malteries, cider plants and other production facilities in more than 70 countries. Most recent information is available on www.heinekenholding.com and www.theheinekencompany.com and follow HEINEKEN on LinkedIn and Instagram.

Attachment

Heineken N.V. reports the progress of transactions under its current share buyback programme

Amsterdam, 14 September 2026 – Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) hereby reports transaction details related to the second € 750 million tranche of its € 1.5 billion share buyback programme as communicated on 12 February 2026.

From 7 September 2026 up to and including 11 September 2026 a total of 167,564 shares were repurchased on exchange at an average price of € 72.01. During the same period, 168,594 shares were repurchased from Heineken Holding N.V.

Up to and including 11 September 2026, a total of 7,186,496 shares were repurchased under the second tranche of the share buyback programme for a total consideration of € 509,660,184 (including shares repurchased from Heineken Holding N.V.).

Heineken N.V. publishes on a weekly basis, every Monday, an overview of the progress of the share buyback programme on its website: https://www.theheinekencompany.com/investors/share-information/share-buyback-programme

Enquiries

Media   Investors
Christiaan Prins   Tristan van Strien
Director of Global Communication   Global Director of Investor Relations
Marlie Paauw   Lennart Scholtus / Isabelle van Rongen
Global Media Lead   Investor Relations Manager / Investor Relations Manager
E-mail: pressoffice@heineken.com   E-mail: investors@heineken.com
Tel: +31-20-5239355   Tel: +31-20-5239590

Regulatory information
This press release is issued in connection with the disclosure and reporting obligations as set out in Article 5(1)(b) Regulation (EU) 596/2014 and Article 2(2) of the Commission Delegated Regulation (EU) 2016/1052 that contains technical standards for buyback programs.

Editorial information:
HEINEKEN is the world’s pioneering beer company. It is the leading developer and marketer of premium and non-alcoholic beer and cider brands. Led by the Heineken® brand, the Group has a portfolio of more than 340 international, regional, local and specialty beers and ciders. With HEINEKEN’s over 85,000 employees, we brew the joy of true togetherness to inspire a better world. Our dream is to shape the future of beer and beyond to win the hearts of consumers. We are committed to innovation, long-term brand investment, disciplined sales execution and focused cost management. Through “Brew a Better World”, sustainability is embedded in the business. HEINEKEN has a well-balanced geographic footprint with leadership positions in both developed and developing markets. We operate breweries, malteries, cider plants and other production facilities in more than 70 countries. Most recent information is available on our Company’s website and follow us on LinkedIn and Instagram.

Attachment

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.